Analisis Saham PT Delta Giri Wacana Tbk (DGWG) Per Q3 Desember 2025
Analisis mendalam saham PT Delta Giri Wacana Tbk (DGWG) per Q3 Desember 2025: skenario harga Rp 500-600, didukung oleh pertumbuhan pendapatan kuat, ekspansi kapasitas agresif, dan dukungan pemerintah terhadap keamanan pangan.
Disclaimer:
Analisis ini adalah opini edukasi, bukan nasihat atau rekomendasi investasi. Kami tidak menerima komisi maupun afiliasi dari emiten yang dibahas. Saham berisiko tinggi—lakukan riset mandiri (DYOR - Do Your Own Research) dan konsultasi dengan penasihat keuangan berlisensi sebelum mengambil keputusan. Hasil masa lalu tidak menjamin kinerja masa depan.
Tanggal Analisis: 7 Januari 2026
Harga Saat Ini: Rp 408 per lembar
Ticker: DGWG (Bursa Efek Indonesia)
Nama Perusahaan: PT Delta Giri Wacana Tbk
Sektor: Industri Proses - Bahan Kimia Pertanian (Agricultural Chemicals, Agro Input, Food Security)
Nilai Pasar: Rp 2.4 Triliun (estimated)
Jumlah Saham Beredar: 5,88 Miliar lembar
Didirikan: 2001 | IPO: 13 Januari 2025 (Brand New Public Company)
Overview: IPO Agrokimia Food Security, Strong Growth Trajectory, Capacity Expansion Aggressive, Government Support Tailwindh2
DGWG adalah perusahaan agrokimia IPO baru dengan trajectory pertumbuhan kuat: Q1 2025 revenue pestisida +18.2% YoY, target 2025 profit +25% pertumbuhan dengan revenue 15-20% growth, kapasitas ekspansi agresif (3 pabrik pupuk baru Sumatra target 2029 = 700K ton dari 300K ton sekarang), methomyl produksi native 2H 2025 startup, dividen interim Rp 8.5 per lembar (2.45% yield) resumed, analyst target Rp 550 (+35% upside), IPO price Rp 230 sekarang Rp 408 (+77% YTD momentum kuat), government food security support strong, market penetration Indonesia masih rendah = huge runway.
DGWG adalah perusahaan agrokimia terintegrasi Indonesia fokus food security dengan portfolio pestisida, pupuk, benih, alat pertanian. Q1 2025 revenue Rp 808M (est), pestisida segment +18.2% YoY ke Rp 291.4M (36% total revenue), volume +17.6%, ASP +0.5% stable. Pupuk segment terbesar dengan ekspansi agresif. Target 2025 full-year: revenue 15-20% growth base Rp 3.4T 2024, profit +25% growth dari laba bersih Rp 180M 2024 guidance ke Rp 225M+ 2025. H2 seasonality strong (musim hujan tinggi = hama serangan peak = pestisida demand spike). Capex expansion ambitious: 3 pabrik pupuk baru Sumatra hingga 2029 (+400K ton capacity), methomyl active ingredient production 2H 2025 (3.3K ton capacity) = supply chain control + margin improvement. Dividen interim Rp 8.5 per lembar announced (2.45% yield), first dividend signal. IPO price Rp 230, now Rp 408 (+77% YTD) = momentum exceptional, foreign buying accumulating (+4-6% foreign stake). P/E 12.8x reasonable for growth company. P/B 2.5x premium justified. Analyst consensus Samuel Rp 550 (+35% upside). Risk manageable: weather risk, delayed capex execution, competitive pressure. Estimasi fair value berada di kisaran Rp 500-600 dalam 12-18 bulan (22-47% di atas harga saat ini).
Status Kini (Data Q1 2025, YTD 2025 Momentum) - IPO GROWTH INFLECTION:
| Item | Nilai | Status |
|---|---|---|
| IPO Price (Jan 13) | Rp 230 | Listing reference |
| Harga Saat Ini | Rp 408 | +77% YTD momentum ✓ |
| Q1 2025 Revenue | Rp 808 Miliar est | Solid start |
| Pestisida Segment | Rp 291.4 Miliar (+18.2% YoY) | Strong growth ✓ |
| Pestisida Volume | +17.6% YoY | Demand robust ✓ |
| Target 2025 Revenue | Rp 3.4-3.6 Triliun | 15-20% growth |
| Target 2025 Profit | Rp 225M+ | +25% YoY growth |
| Dividen Interim 2025 | Rp 8.5 per lembar | 2.45% yield ✓ |
| Analyst Target (Samuel) | Rp 550 | +35% upside |
| Kapasitas Pupuk | 300K ton current → 700K ton 2029 | Massive expansion ✓ |
| Methomyl Production | Start 2H 2025 (3.3K ton) | Supply chain control ✓ |
| Foreign Buying | +4-6% accumulation | Institutional interest ✓ |
| P/E (TTM) | 12.8x | Fair for growth |
| P/B Ratio | 2.5x | Premium justified |
| Momentum YTD | +77% | Exceptional |
Profil Agrokimia IPO Growth:
- ✓ IPO momentum exceptional - +77% since Rp 230 IPO price Jan 2025
- ✓ Revenue growth strong - Q1 +18.2% pestisida, 2025 target 15-20% total
- ✓ Profit growth acceleration - 2025 target +25% from Rp 180M baseline
- ✓ Capacity expansion aggressive - 3 plants Sumatra, 700K ton target 2029
- ✓ Supply chain integration - Methomyl production 2H 2025 = margin boost
- ✓ Dividen resumed - Rp 8.5 interim (2.45% yield) attractive
- ✓ Government support - Food security focus, farmer demand strong
- ✓ Analyst target visible - Rp 550 (+35% upside from current)
Kesimpulan Awal: DGWG adalah IPO AGROKIMIA GROWTH STORY - Food security mandate, revenue growth double-digit, profit inflection +25%, capacity expansion triple scale, government support strong, IPO momentum exceptional, dividen attractive, analyst target clear. Karakter saham ini bercirikan growth dan terkait erat dengan tema transformasi pertanian Indonesia.
ANALISIS FUNDAMENTAL - 5 PILAR (GROWTH INFLECTION CLEAR)h2
PILAR 1: PROFITABILITAS & MARGINh3
Status: ✓ GROWTH INFLECTION CLEAR, ACCELERATION VISIBLE
✓ 2025 profit target +25% YoY - Strong inflection from Rp 180M baseline.
✓ Q1 2025 pestisida +18.2% YoY - Healthy organic growth momentum.
✓ Volume growth +17.6%, ASP stable +0.5% - Quality growth visible (volume-driven).
✓ H2 seasonality strong - Musim hujan = peak demand pestisida expected.
✓ Methomyl production 2H 2025 - Supply chain control = margin expansion ahead.
Assessment: Profitability inflection clear = GROWTH ACCELERATION TRAJECTORY.
PILAR 2: ARUS KAS & PEMBIAYAANh3
Status: ✓ CAPEX-HEAVY BUT INTERNALLY FUNDED, HEALTHY BALANCE
✓ IPO capital raised - Rp 200M+ funding untuk capex, working capital.
✓ Capex aggressive 3 plants Sumatra - Phased 2025-2029, internally manageable.
✓ Operating cashflow strong - Revenue growth driving positive OCF.
✓ Dividen resumed - Rp 8.5 interim signals confidence in cashflow.
Assessment: Cashflow positioned well = SELF-FUNDING CAPACITY for expansion.
PILAR 3: UTANG & SOLVABILITASh3
Status: ✓ POST-IPO STRONG, BALANCE SHEET HEALTHY
✓ IPO capital boost - Reduced financial leverage risk.
✓ Debt levels manageable - Agro sector standard, no solvency stress.
✓ Current ratio healthy - Working capital adequate for growth phase.
✓ No bankruptcy risk - Solid balance sheet position.
Assessment: Solvency excellent = FINANCIAL FLEXIBILITY for capex.
PILAR 4: HASIL INVESTASI & RETURNh3
Status: ✓ IMPROVING RAPIDLY, CAPACITY RAMP WILL DRIVE ROIC
✓ ROE improving - Profit growth (+25% target) lifting returns.
✓ ROIC will expand 2026+ - New plants (Sumatra, methomyl) high-margin.
✓ Capital employed efficiently - Capex disciplined, revenue growth organic + inorganic.
✓ Dividend + capital appreciation - Dual return stream attractive.
Assessment: Returns rebuilding = STRONG INFLECTION TRAJECTORY 2026+.
PILAR 5: DIVIDEN & RETURN PEMEGANG SAHAMh3
Status: ✓ DIVIDEND RESUMED, CAPITAL APPRECIATION STRONG
✓ Dividen interim Rp 8.5 - 2.45% yield attractive for growth stock.
✓ IPO momentum +77% YTD - Capital appreciation exceptional.
✓ Expected return 30-40% - Dividen + growth upside strong.
✓ Stock at discount to analyst target - Rp 550 (+35% visible).
Assessment: Shareholder return = EXCELLENT combined dividen + growth.
RINGKASAN 5 PILARh2
| Pilar | Status | Nilai |
|---|---|---|
| 1. Profitabilitas | ✓ Growth inflection clear | 4/5 |
| 2. Arus Kas | ✓ Capex-heavy but funded | 3.5/5 |
| 3. Utang & Solvabilitas | ✓ Healthy post-IPO | 4/5 |
| 4. Return Investasi | ✓ Improving rapidly | 3.5/5 |
| 5. Dividen | ✓ Resumed 2.45% yield | 3.5/5 |
| RATA-RATA | ✓ IPO GROWTH STORY | 3.7/5 |
Score 3.7/5 Good (strong growth trajectory). IPO quality improving.
VALUASI & FAIR VALUEh2
Fair Value Estimation (Growth IPO Model):
| Model | Fair Value | Current (Rp 408) | Upside |
|---|---|---|---|
| P/E 14x (normalized 2025) | Rp 475-525 | Rp 408 | +16-29% |
| P/B 3.0x (growth premium) | Rp 550-650 | Rp 408 | +35-59% |
| PEG 0.5x (growth-adjusted) | Rp 500-600 | Rp 408 | +22-47% |
| Analyst consensus (Samuel) | Rp 550 | Rp 408 | +35% |
| Bull case (2027 capex ramp) | Rp 700-800 | Rp 408 | +72-96% |
🟢 CONSENSUS FAIR VALUE Rp 500-600 = Current Rp 408 at discount 15-32%.
SKENARIO 2-TAHUNh2
| Scenario | Probability | Return | Target | Narrative |
|---|---|---|---|---|
| Bull | 40% | +60% | Rp 653 | Capex ramp ahead schedule, profit +35%, margins +300bp, methomyl production success |
| Base | 45% | +35% | Rp 550 | Steady growth, capex on-track, profit +25%, margins stable |
| Bear | 15% | -20% | Rp 326 | Capex delays, competitive intensity, margin pressure, weather risk |
| Expected | +32% | Rp 539 | Probability-weighted STRONG return |
🟢 Expected return +32% over 2Y + dividen 2-3% CAGR = 5-6% total return solid.
Ringkasan & Level Teknikal Kuncih2
Faktor pendukung tesis:
- IPO momentum exceptional +77% YTD (Rp 230 → Rp 408)
- Revenue growth strong Q1 +18.2% pestisida YoY
- Profit target +25% 2025 clear inflection
- Capacity expansion aggressive (3 plants, 700K ton 2029)
- Supply chain integration (methomyl 2H 2025)
- Government food security support tailwind
- Dividen resumed 2.45% yield attractive
- Analyst target Rp 550 (+35% visible)
- Foreign buying accumulating (quality signal)
- Market penetration Indonesia still low (runway huge)
Secara level harga, zona Rp 380-395 berada di area pelemahan/dip dari harga saat ini (Rp 408); Rp 450-500 mendekati estimasi fair value awal; zona Rp 550-600 mencerminkan skenario di mana sebagian besar upside sudah terealisasi; di atas Rp 700 valuasi mulai mencerminkan skenario fair value penuh terlampaui.
Katalis Kunci (2026):
| Event | Timeline | Impact |
|---|---|---|
| 2025 full-year results | Feb 2026 | Confirm +25% profit growth guidance |
| Methomyl production ramp | Q2-Q3 2026 | Supply chain benefits visible in margin |
| First Sumatra plant groundbreaking | Q2-Q3 2026 | Capex execution confidence |
| 2026 guidance upgrade | May 2026 | Expect +20% profit growth 2026 |
| Dividen payment | Jun 2026 | Consistent dividen signal |
Siklus capex ramp dan visibilitas profit inflection relevan pada horizon 12-24 bulan.
KOMPETITOR, ANCAMAN, PELUANGh2
Competitive Landscape (Agrokimia Indonesia):
DGWG competitor dengan BISI (Benih Industri), Syngenta, Corteva lokal. DGWG unique as diversified (pestisida + pupuk + alat) vs specialized competitors.
Ancaman (Manageable):
- 🟡 Competitive intensity (BISI, Syngenta have scale advantages)
- 🟡 Weather risk (drought = reduced pestisida demand)
- 🟡 Commodity price volatility (raw material input costs)
Peluang (Strong Government Support):
- 🟢 Food security mandate Indonesia (government priority)
- 🟢 Domestic market penetration (farmer adoption still growing)
- 🟢 Capacity expansion (Sumatra plants filling unmet demand)
- 🟢 Supply chain integration (methomyl production margin upside)
- 🟢 Export opportunities (ASEAN agricultural integration)
KESIMPULANh2
DGWG adalah IPO AGROKIMIA DENGAN STRONG GROWTH TRAJECTORY + GOVERNMENT FOOD SECURITY SUPPORT.
Strengths:
- ✓ IPO momentum exceptional +77% YTD (strength signal)
- ✓ Revenue growth strong +18.2% Q1 pestisida
- ✓ Profit inflection clear +25% target 2025
- ✓ Capacity expansion aggressive (700K ton 2029 vs 300K now)
- ✓ Supply chain integration (methomyl 2H 2025)
- ✓ Government support strong (food security priority)
- ✓ Dividen resumed attractive (2.45% yield)
- ✓ Analyst target clear Rp 550 (+35% upside)
- ✓ Valuation fair P/E 12.8x for growth company
- ✓ Market opportunity huge (Indonesia farmer adoption low)
Weaknesses (Manageable):
- 🟡 IPO new (execution risk on capex projects)
- 🟡 Competitive pressure (BISI, Syngenta have scale)
- 🟡 Weather dependent (drought risk to demand)
- 🟡 Capex execution (3 plants on-time/budget)
Profil saham ini bercirikan growth dan terkait dengan tema transformasi pertanian/food security Indonesia, dengan horizon 12-24 bulan.
Expected Return: +32% capital (2Y) + 2-3% dividen = 5-6% CAGR solid.
Secara ringkas, harga Rp 408 saat ini berada di bawah estimasi fair value Rp 500-600 (22-47% di bawahnya), dengan trajectory growth IPO yang jelas, tailwind food security yang kuat, ekspansi kapasitas yang ambisius, target analis yang visible, momentum yang kuat, dan dividen yang menarik mendukung skenario tersebut terealisasi dalam 12-18 bulan ke depan.
Analisis dibuat 7 Januari 2026 berdasarkan Q1 2025 performance, 2025 full-year guidance, IPO January 2025 context, capex expansion strategy, analyst consensus, dan momentum exceptional YTD +77%.
Comments